1185112-19-9
Chemical Structure
4-Hydroxytolbutamide-d9
Synonym(s): Hydroxytolbutamide-d9
- CAS No.: 1185112-19-9
- Formula:C12H9D9N2O4S
- Molecular Weight:295.40
IUPAC Name: N-((butyl-d9)carbamoyl)-4-(hydroxymethyl)benzenesulfonamide
InChIKey: SJRHYONYKZIRPM-WRMMWXQOSA-N
SMILES: O=S(C1=CC=C(CO)C=C1)(NC(NC([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])=O)=O
Biological Activity: 4-Hydroxytolbutamide-d9 is the deuterium labeled 4-Hydroxytolbutamide. 4-Hydroxytolbutamide (Hydroxytolbutamide) is a metabolite of Tolbutamide. 4-Hydroxytolbutamide is metabolized by CYP2C8 and CYP2C9. Tolbutamide is a first generation potassium channel blocker and a sulfonylurea oral antidiabetic[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
4-Hydroxytolbutamide-d9 | 99.29% | 4-Hydroxytolbutamide-d9 is the deuterium labeled 4-Hydroxytolbutamide. 4-Hydroxytolbutamide (Hydroxytolbutamide) is a metabolite of Tolbutamide. 4-Hydroxytolbutamide is metabolized by CYP2C8 and CYP2C9. Tolbutamide is a first generation potassium channel blocker and a sulfonylurea oral antidiabetic. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
4-Hydroxytolbutamide-d9-1 | 4-Hydroxytolbutamide-d9-1 (Hydroxytolbutamide-d9-1) is the deuterium labeled 4-Hydroxytolbutamide (HY-100641). 4-Hydroxytolbutamide (Hydroxytolbutamide) is a metabolite of Tolbutamide. 4-Hydroxytolbutamide is metabolized by CYP2C8 and CYP2C9. Tolbutamide is a first generation potassium channel blocker and a sulfonylurea oral antidiabetic. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
4-Hydroxytolbutamide | 99.69% | 4-Hydroxytolbutamide (Hydroxytolbutamide) is a metabolite of Tolbutamide. 4-Hydroxytolbutamide is metabolized by CYP2C8 and CYP2C9. Tolbutamide is a first generation potassium channel blocker and a sulfonylurea oral antidiabetic. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Hansen LL, et al. Quantitative determination of tolbutamide and its metabolites in human plasma and urine by high-performance liquid chromatography and UV detection. Ther Drug Monit. 1999 Dec;21(6):664-71. [Content Brief]
